CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.35
+7.80%Oct 29, 2026, 12:00 UTC
CytomX Therapeutics, Inc. announced that it will report its third-quarter 2026 financial results after the close of U.S. markets on November 5, 2026.
Source:Aug 7, 2026, 00:12 UTC
CytomX Therapeutics reported a Q2 2026 loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.11, compared to break-even earnings per share a year ago.
Source:Jul 27, 2026, 00:00 UTC
CytomX Therapeutics appointed Charles Fuchs, M.D., M.P.H. as a Class II director, effective July 24, 2026.
Jun 4, 2026, 18:25 UTC
Regeneron expands its partnership with CytomX to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
Source:Jun 3, 2026, 00:00 UTC
CytomX Therapeutics amended its collaboration and license agreement with Regeneron Pharmaceuticals, extending Regeneron's program selection period and allowing up to eight new collaboration programs, with Regeneron nominating the first two programs and CytomX receiving $37.0 million in aggregate target nomination payments.
Source: